Abstract: Methods for suppressing IgE-mediated anaphylaxis are provided herein, which include administering to a person in need thereof a combination of at least two therapeutic agents selected from the group consisting of an antihistamine, one or more beta-adrenergic agonists, and one or more tyrosine kinase antagonists. Also provided herein are methods of suppressing IgE-mediated anaphylaxis associated with immunotherapeutic desensitization of a subject, and pharmaceutical compositions for suppressing IgE-mediated anaphylaxis.

Abstract: Systems, methods and computer storage mediums accurately measure wall thickness in a region of interest included in complex curved structures. Embodiments of the present disclosure relate to generating a wall thickness loss distribution map of a region of interest that provides an accurate representation of wall thickness for the region of interest included in a complex curved structure. The wall thickness loss distribution map is generated from a two-dimensional model of the wall thickness loss distribution of the region of interest. The two-dimensional model is converted from a three-dimensional representation of the wall thickness loss distribution of the region of interest. The three-dimensional representation of the wall thickness is generated by ultrasonic waves generated by a transducer system that propagated through the region of interest.

Abstract: Synthesis and pharmaceutical compositions of antibody-functionalized nanovesicles encapsulating ion channel knockout siRNA, and methods of treating autoimmune diseases associated with increased expression and/or hyperactivity of T cells by selectively targeting memory T cells with the nanoparticles, which deliver their siRNA cargo into the cytosol of the TM cell thus reducing ion channel expression and decreasing Ca2+ influx.

Abstract: The present invention provides compositions and methods useful for treating cancers such as glioblastoma. SapC-DOPS was found to be synergistically effective at inducing cell death when administered in conjunction with rapamycin. SapC-DOPS/rapamycin combination therapy allows physicians to give lower doses of each drug and achieve better therapeutic efficacy. The compositions also allow for less toxicity and fewer off-target effects. Related methods and materials are also provided herein.

Abstract: Methods for treating a cocaine-related disorder in an individual include administering to the individual a therapeutic amount of an antibody comprising a human immunoglobulin gamma heavy chain and a murine lambda light chain. In another embodiment, the light chain includes a human kappa light chain at least partially derived from 1B3. Other embodiments are directed toward the antibodies themselves and methods of binding the antibodies.

Abstract: A method for manufacturing a freestanding film having at least one population of through holes cumulatively totaling at least 1% of the film area, wherein the standard deviation of hole diameters is less than 25% and a thickness less than 25 micrometers, The film provides a carrier substrate, a photo-curable material, a release agent and deposits a photo-curable material on the substrate, selectively curing the material and leaving uncured material in the pattern of holes, dissolving away the uncured material and removing the cured material from the carrier. Methods and apparatus are described.

Abstract: A method for annealing multi-walled carbon nanotubes includes applying a high-frequency electromagnetic field to the carbon nanotubes and causing the carbon nanotubes to self-heat to a temperature and for a time effective to reduce defects and reduce a number of walls in some of the carbon nanotubes.

Abstract: The presently disclosed subject matter relates to enhanced dry-cooling systems and methods. More specifically, the presently disclosed subject matter relates to enhanced dry-cooling systems for increasing power plant efficiency and output. One embodiment of the present disclosure is directed to dry-cooling system for increasing power plant efficiency and output. The dry-cooling system comprises an air-cooled condenser and an air cooling system in fluid communication with the air-cooled condenser.

Abstract: Methods for treating type one diabetes mellitus in a subject in need thereof and pharmaceutical compositions for the treatment of type one diabetes mellitus are disclosed, including combination therapies with insulin. The methods include administering an effective amount of apolipoprotein A-IV to the subject having type I diabetes. The pharmaceutical composition includes apolipoprotein A-IV formulated for administration to a subject for the treatment of type one diabetes mellitus.

Abstract: A self-healing coating composition for use on metals includes a polyurea, an epoxy ester unsaturated resin, a combination of amine terminated siloxane and epoxy terminated siloxane and an organoclay. The polyurea is a water-soluble, aromatic polyurea and likewise, the epoxy ester is a water-soluble, aromatic epoxy ester. The coating composition is formed in a non-volatile solvent, such as N-Methylpyrrolidone. It can be applied to a metal surface and cured at room temperature to form a coating that is resistant to corrosion. Further the coating self-heals in a manner similar to a chromate coating.

Abstract: Systems, methods and computer storage mediums accurately measure wall thickness in a region of interest included in complex curved structures. Embodiments of the present disclosure relate to generating a wall thickness loss distribution map of a region of interest that provides an accurate representation of wall thickness for the region of interest included in a complex curved structure. The wall thickness loss distribution map is generated from a two-dimensional model of the wall thickness loss distribution of the region of interest. The two-dimensional model is converted from a three-dimensional representation of the wall thickness loss distribution of the region of interest. The three-dimensional representation of the wall thickness is generated by ultrasonic waves generated by a transducer system that propagated through the region of interest.

Abstract: The present disclosure relates to the field of cancer treatment, and more specifically to the field of treatment of primary malignant brain tumors. Provided herein are methods of treating primary brain tumors, including gliomas, by administering to a patient in need thereof a therapeutically effective amount of the aromatase inhibitor letrozole.

Abstract: Methods and systems for passively detecting stable cavitation and enhancing stable cavitation during sonothrombolysis are provided. The method of passively detecting stable cavitation includes providing a determined level of ultrasonic energy and detecting a scattered level of ultrasonic energy. The system for inducing and passively detecting stable cavitation includes a dual-element annular transducer array configured to provide a fundamental ultrasonic frequency and to detect an ultrasonic frequency that is a derivative of the fundamental frequency. The method of enhancing stable cavitation includes administering a nucleating agent and a thrombolytic agent to a treatment zone, providing a determined level of ultrasonic energy, and detecting a scattered level of ultrasonic energy.

Abstract: Synthetic ligand compounds and methods of differentiating between Shiga toxin 1 and Shiga toxin 2 are disclosed herein. Another embodiment includes a kit for differentiating between Shiga toxin 1 and Shiga toxin 2. Assay systems and methods for providing an assay are also provided for herein.

Abstract: Methods and systems for inducing and passively detecting stable cavitation and/or inertial cavitation for targeted drug delivery across a biological membrane are disclosed. Such methods include administering vesicles having a nucleating agent and a therapeutic drug to a vascular system of a patient, and providing an active interval of ultrasonic exposure substantially throughout a targeted treatment zone. The ultrasonic exposure is produced by a source transducer at a specified fundamental frequency, amplitude, duty cycle, and duration. The methods also include detecting a scattered ultrasonic wave, where the scattered ultrasonic wave is received by a detection transducer. Detection of the scattered ultrasonic wave is indicative of stable and/or inertial cavitation. The ultrasonic exposure is provided intermittently in the active intervals separated by rest periods, and substantially less ultrasonic exposure is provided during the rest period than during the active interval.

Abstract: Methods for making a magnesium biodegradable stent for medical implant applications, using magnesium foil or pure magnesium or magnesium alloys that are biodegradable and performing a lithographic technique to configure the features and dimensions of the magnesium foil, and rolling the magnesium foil to form a cylinder.

Abstract: A method for manufacturing an electrofluidic device comprising the steps of providing a first plate with features for holding a first fluid, filling a first fluid into features on a first plate; providing a second plate and sealing a second plate onto the first plate forming stacked plates with at least one cavity between the plates, and leaving at least one fill port for a second fluid. Thereafter, the stacked plates are cooled to increase the viscosity of the first fluid so that the first fluid maintains a fixed position as a second fluid is filled into the cavity. Methods are disclosed.

Abstract: A sweat sensor device (200) includes one or more sweat sensors (220) and a seal (280) covering the one or more sweat sensors (220). The seal (280) is adapted to protect the sweat sensors (220) from outside contaminants when the device (200) is placed on the skin (12). The sweat sensor device (200) may include an absorbing medium (230) to absorb sweat from the skin (12) that is covered by the seal (280). The seal (280) can be permeable to gas, permeable to water and impermeable to at least one aqueous solute, or selectively permeable to at least one aqueous solute. The sweat sensor device (200) may include an artificial sweat stimulation mechanism (345) for stimulating sweat when the device (200) is placed on the skin (12).

Abstract: An electronic sweat sensor (300) includes a plurality of porous substrates (310, 312), each porous substrate (310, 312) having an electrically conductive surface (320, 322). The porous substrates (310, 312) have a generally planar surface. The generally planar surface may be adapted to be positioned on skin (12) generally coplanar with the skin. The electronic sweat sensor (300) further includes a porous spacer (315) layer defining a gap between at least two of the porous substrates (310, 312). When an analyte flow (305), which may be from skin (12), is moving perpendicular to the planar surface and through at least one of the porous substrates (310, 312), at least one of the conductive surfaces (320, 322) provides an electrical response to the presence of the analyte flow (305).

Abstract: A device (10) and method for analyzing blood coagulation in a blood sample. The device (10) includes a housing (12) having an analytical membrane (14) partially enclosed in a housing. The analytical membrane (14) includes a porous hydrophilic sample portion (34), a porous hydrophilic analytical portion (36), and a porous hydrophilic wicking portion (38). The porosity of the analytical portion (36) differs from the porosity of the sample portion (34). The method utilizes the device to analyze blood coagulation in a whole blood sample from the distance travelled by the red blood cell leading edge (50) in a predetermined period of time.